Bacterial Lipopolysaccharide as Adjuvants

摘要: Lipopolysaccharide (LPS, endotoxin) is a major component of the outer membrane gram negative bacteria. It an activator humoral and cellular responses in humans with potential use as adjuvant vaccine technology. Importantly, LPS has large capacity to induce Th1-type stimulate cytotoxic T lymphocytes, which are poorly obtained by standard adjuvants but required for specific immune stimulatory therapies. In contrast, possess extreme toxicity that limit its clinical humans. Alteration chemical structure led generation LPS-based derivatives reduced retaining properties. Monophosphoryl lipid A (MPLA) been most successful adjuvant, currently incorporated approved preparations extensively used trials preclinical studies. Novel designed structures, analogous generated synthesis, can offer lower production cost lesser heterogenic formulations than MPLA and, addition, be even suitable Thus, structures valuable contributions human vaccinology open new possibilities existing demands